Compare iShares MSCI Taiwan ETF (EWT) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Taiwan ETF vs TG Therapeutics Inc — how do they compare? iShares MSCI Taiwan ETF trades at $114.19 (market cap $12.74B), while TG Therapeutics Inc trades at $55.24 (market cap $8.16B). The key difference: iShares MSCI Taiwan ETF is the larger of the two by market cap, and iShares MSCI Taiwan ETF is more actively traded (8,470,920 versus 1,735,121). Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Taiwan ETF for 52 Days and TG Therapeutics Inc for 16 Days on average.
| EWT | TGTX | |
|---|---|---|
Market Cap | $12.74B | $8.16B |
Volume | 8,470,920 | 1,735,121 |
Sector | Broad Market / Factor | Health |
52-Week High | $118.00 | $59.06 |
52-Week Low | $60.03 | $26.94 |
Typical Hold Time | 52 Days | 16 Days |
Enterprise Value | — | $8.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWT (iShares MSCI Taiwan ETF) trades at $114.16, down 1.79% on the day, with a bullish technical signal from moving averages while oscillators remain neutral. The ETF maintains strong exposure to Taiwan's semiconductor sector, particularly TSMC, benefiting from AI-driven demand. Recent news highlights Taiwan's strategic position in AI supply chains with companies planning significant US investments.
The outlook remains positive given Taiwan's dominance in semiconductor manufacturing and AI growth potential, though geopolitical risks and concentration in technology stocks present notable challenges. Institutional interest continues with Bank of America increasing its stake, supporting the ETF's long-term growth narrative despite near-term volatility.
TG Therapeutics (TGTX) trades at $54.80, up 3.49% today, but faces a bearish technical signal with recent earnings misses. Revenue growth is strong, with 2026 guidance raised to $950M for BRIUMVI, and net income margins exceed 55%. However, cash flow was negative in 2025, and a shareholder litigation investigation adds near-term uncertainty.
The outlook is mixed: analyst consensus is bullish with an $80.50 price target, but execution risks and earnings volatility persist. Upside hinges on BRIUMVI market share gains and subcutaneous formulation progress, while legal and competitive pressures pose threats to shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares MSCI Taiwan ETF
EWT tracks the MSCI Taiwan 25/50 Index, providing targeted exposure to large and mid-cap companies in Taiwan. It is heavily concentrated in the information technology sector, serving as a liquid instrument for investors seeking a single-country view of Taiwan's export-oriented and tech-driven economy.
Read more on EWT →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
